Company attributes
Other attributes
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company that develops therapies for people with rare endocrine diseases. It works on finding therapies that provide effective disease control and simplicity in patients' lives. Crinetics Pharmaceuticals partners with healthcare practitioners to ensure real problems are being solved for them.
Crinetics Pharmaceuticals was launched by a team of scientists with a history of drug discovery and development. It is dedicated to developing significant new therapeutic options for patients that are with rare endocrine diseases.
Its lead product candidate, paltusotine (formerly CRN00808), is an oral selective nonpeptide somatostatin receptor type 2 biased agonist undergoing two Phase 2 clinical trials for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States.
Crinetics Pharmaceuticals is developing an oral nonpeptide somatostatin receptor type 5 (sst5) agonist for hyperinsulinism, and an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease, congenital adrenal hyperplasia and other diseases of excess ACTH.
